A Randomised, Double-blind, Placebo-controlled, Two-period, Two-sequence-crossover Interaction Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease
Phase of Trial: Phase I/II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Safinamide (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Newron Pharmaceuticals; Newron Sweden AB
- 14 Sep 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 14 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Dec 2009 New trial record